Table 1.

Correlation of NY-ESO-1 antibody at baseline (before treatment) with clinical course following anti–CTLA-4 treatment

Response at wk 24Total (%)NY-ESO-1 seronegativeNY-ESO-1 seropositive
Clinical benefit48 (34.3)36 (30.5)12 (54.6)
Complete response4 (2.9)31
Partial response14 (10.0)104
Stable disease30 (21.4)237
No clinical benefit92 (65.7)82 (69.5)10 (45.4)
Total14011822
  • Patients seropositive for NY-ESO-1 are more likely to experience disease control than seronegative patients [P = 0.0481, RR = 1.8 (1.1–2.9), two-tailed Fisher test].